BG107909A - "'илва'...ли на gaba при л...-...ни... на бол...''и, 'вързани ' намал...на н...вро''...роидна ак'ивно'' - Google Patents

"'илва'...ли на gaba при л...-...ни... на бол...''и, 'вързани ' намал...на н...вро''...роидна ак'ивно'' Download PDF

Info

Publication number: BG107909A
Authority: BG; Bulgaria
Prior art keywords: gaba; neurosteroid; disorder; compound; disease
Prior art date: 2000-11-20

Application number

BG107909A

Other languages

Bulgarian (bg)

English (en)

Inventor

Bjarke Ebert

Peter Hongaard Andersen

Original Assignee

H. Lundbeck A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-20

Filing date

2003-06-13

Publication date

2004-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG107909(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-06-13 Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S

2004-08-31 Publication of BG107909A publication Critical patent/BG107909A/bg

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 38
230000000694 effects Effects 0.000 title claims abstract description 31
239000003623 enhancer Substances 0.000 title claims abstract description 7
201000010099 disease Diseases 0.000 title claims description 15
230000002829 reductive effect Effects 0.000 title abstract description 6
208000035475 disorder Diseases 0.000 claims abstract description 23
239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 claims abstract description 7
229940091860 GABA uptake inhibitor Drugs 0.000 claims abstract description 6
239000002843 gaba uptake inhibitor Substances 0.000 claims abstract description 6
150000001875 compounds Chemical class 0.000 claims description 34
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 28
239000000186 progesterone Substances 0.000 claims description 14
229960003387 progesterone Drugs 0.000 claims description 14
230000003637 steroidlike Effects 0.000 claims description 13
ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims description 7
210000004556 brain Anatomy 0.000 claims description 7
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 6
ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
150000003146 progesterones Chemical class 0.000 claims description 5
201000009916 Postpartum depression Diseases 0.000 claims description 4
230000003247 decreasing effect Effects 0.000 claims description 4
230000001544 dysphoric effect Effects 0.000 claims description 4
PRJKNHOMHKJCEJ-UHFFFAOYSA-N imidazol-4-ylacetic acid Chemical compound OC(=O)CC1=CN=CN1 PRJKNHOMHKJCEJ-UHFFFAOYSA-N 0.000 claims description 4
229960002870 gabapentin Drugs 0.000 claims description 3
229950004346 gaboxadol Drugs 0.000 claims description 2
230000000737 periodic effect Effects 0.000 claims description 2
230000000306 recurrent effect Effects 0.000 claims description 2
230000009467 reduction Effects 0.000 claims description 2
PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims description 2
229960001918 tiagabine Drugs 0.000 claims description 2
229960003692 gamma aminobutyric acid Drugs 0.000 claims 3
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 3
238000004519 manufacturing process Methods 0.000 claims 1
102000005915 GABA Receptors Human genes 0.000 abstract description 5
108010005551 GABA Receptors Proteins 0.000 abstract description 5
-1 steroid compound Chemical class 0.000 abstract description 4
230000003371 gabaergic effect Effects 0.000 abstract 1
102000005962 receptors Human genes 0.000 description 23
108020003175 receptors Proteins 0.000 description 23
229940049706 benzodiazepine Drugs 0.000 description 11
241001465754 Metazoa Species 0.000 description 9
206010036618 Premenstrual syndrome Diseases 0.000 description 9
238000012360 testing method Methods 0.000 description 9
150000001557 benzodiazepines Chemical class 0.000 description 8
208000019901 Anxiety disease Diseases 0.000 description 6
208000027030 Premenstrual dysphoric disease Diseases 0.000 description 6
230000036506 anxiety Effects 0.000 description 6
239000002775 capsule Substances 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
239000007943 implant Substances 0.000 description 5
239000002858 neurotransmitter agent Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
241000699670 Mus sp. Species 0.000 description 4
239000000556 agonist Substances 0.000 description 4
230000037396 body weight Effects 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 3
206010010904 Convulsion Diseases 0.000 description 3
230000006399 behavior Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000000243 solution Substances 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
230000000971 hippocampal effect Effects 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000005499 meniscus Effects 0.000 description 2
238000000034 method Methods 0.000 description 2
230000027758 ovulation cycle Effects 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
239000007787 solid Substances 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
230000000542 thalamic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
AELCINSCMGFISI-DTWKUNHWSA-N (1R,2S)-tranylcypromine Chemical compound N[C@@H]1C[C@H]1C1=CC=CC=C1 AELCINSCMGFISI-DTWKUNHWSA-N 0.000 description 1
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
OUENRUZPZZFMCA-YFKPBYRVSA-N 2-[(3s)-pyrrolidin-1-ium-3-yl]acetate Chemical compound OC(=O)C[C@@H]1CCNC1 OUENRUZPZZFMCA-YFKPBYRVSA-N 0.000 description 1
DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
101150025690 CA5A gene Proteins 0.000 description 1
AOAFGVWKONLQRN-OQKWZONESA-N Cc1cc(Cl)cc(\C(=N\CCCC(N)=O)c2ccc(Cl)cc2)c1O Chemical compound Cc1cc(Cl)cc(\C(=N\CCCC(N)=O)c2ccc(Cl)cc2)c1O AOAFGVWKONLQRN-OQKWZONESA-N 0.000 description 1
108010062745 Chloride Channels Proteins 0.000 description 1
102000011045 Chloride Channels Human genes 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
229920002274 Nalgene Polymers 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
229960003305 alfaxalone Drugs 0.000 description 1
230000008860 allosteric change Effects 0.000 description 1
230000003281 allosteric effect Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229960000794 baclofen Drugs 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000027046 diestrus Effects 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003596 drug target Substances 0.000 description 1
230000001490 effect on brain Effects 0.000 description 1
230000001158 estrous effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229960004391 lorazepam Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000002175 menstrual effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000036407 pain Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
SRPNQDXRVRCTNK-UHFFFAOYSA-N pivagabine Chemical compound CC(C)(C)C(=O)NCCCC(O)=O SRPNQDXRVRCTNK-UHFFFAOYSA-N 0.000 description 1
229960003084 pivagabine Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000006748 scratching Methods 0.000 description 1
230000002393 scratching effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229920000260 silastic Polymers 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000012353 t test Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
229950000583 tolgabide Drugs 0.000 description 1
PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
229960005318 vigabatrin Drugs 0.000 description 1
229960002911 zonisamide Drugs 0.000 description 1
UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Indole Compounds (AREA)
Hydrogenated Pyridines (AREA)

BG107909A 2000-11-20 2003-06-13 "'илва'...ли на gaba при л...-...ни... на бол...''и, 'вързани ' намал...на н...вро''...роидна ак'ивно'' BG107909A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200001743		2000-11-20
PCT/DK2001/000773 WO2002040009A1 (en)	2000-11-20	2001-11-20	Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity

Publications (1)

Publication Number	Publication Date
BG107909A true BG107909A (bg)	2004-08-31

Family

ID=8159857

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107909A BG107909A (bg)	2000-11-20	2003-06-13	"'илва'...ли на gaba при л...-...ни... на бол...''и, 'вързани ' намал...на н...вро''...роидна ак'ивно''

Country Status (33)

Country	Link
US (2)	US20040024038A1 (cs)
EP (1)	EP1337247B1 (cs)
JP (1)	JP4152186B2 (cs)
KR (1)	KR100865651B1 (cs)
CN (1)	CN1318027C (cs)
AR (1)	AR031473A1 (cs)
AT (1)	ATE336242T1 (cs)
AU (2)	AU2351402A (cs)
BG (1)	BG107909A (cs)
BR (1)	BR0115668A (cs)
CA (1)	CA2429220C (cs)
CY (1)	CY1106209T1 (cs)
CZ (1)	CZ20031383A3 (cs)
DE (1)	DE60122368T2 (cs)
DK (1)	DK1337247T3 (cs)
EA (1)	EA007287B1 (cs)
ES (1)	ES2266308T3 (cs)
HR (1)	HRP20030404A2 (cs)
HU (1)	HUP0400505A3 (cs)
IL (1)	IL155587A0 (cs)
IS (1)	IS2427B (cs)
ME (1)	MEP6408A (cs)
MX (1)	MXPA03004349A (cs)
NO (1)	NO20032271D0 (cs)
NZ (1)	NZ525520A (cs)
PL (1)	PL361051A1 (cs)
PT (1)	PT1337247E (cs)
SI (1)	SI1337247T1 (cs)
SK (1)	SK7682003A3 (cs)
UA (1)	UA77403C2 (cs)
WO (1)	WO2002040009A1 (cs)
YU (1)	YU39003A (cs)
ZA (1)	ZA200303289B (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8048917B2 (en)	2005-04-06	2011-11-01	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
WO2003045411A2 (de) *	2001-11-26	2003-06-05	Finzelberg Gmbh & Co. Kg	Ingwer-extraktzubereitung
EP1641456B1 (en) *	2003-06-25	2010-03-03	H. Lundbeck A/S	Gaboxadol for treating depression and other affective disorders
GB0402118D0 (en)	2004-01-30	2004-03-03	Merck Sharp & Dohme	Polymorphic forms of a GABAA agonist
MXPA06015196A (es) *	2004-06-29	2007-03-15	Lundbeck & Co As H	Tratamiento del dolor neuropatico, la fibromialgia o la artritis reumatoide.
WO2006012563A2 (en) *	2004-07-23	2006-02-02	The Regents Of The University Of California	Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
GB0417558D0 (en) *	2004-08-06	2004-09-08	Merck Sharp & Dohme	Novel combination therapy
EP1848420A4 (en)	2005-01-28	2008-01-23	Merck & Co Inc	POLYMORPH SHAPES OF A GABAA AGONIST
US20070122507A1 (en) *	2005-05-26	2007-05-31	Palu Afa K	Histone deacetylase and tumor necrosis factor converting enzyme inhibition
WO2008085205A2 (en) *	2006-12-29	2008-07-17	Prodea Systems, Inc.	System and method for providing network support services and premises gateway support infrastructure
WO2008141112A1 (en) *	2007-05-09	2008-11-20	Cenerx Biopharma, Inc.	Methods of treating rett syndrome
CN101585862B (zh) *	2008-05-20	2014-12-17	梅克芳股份公司	甾族化合物
WO2012173634A1 (en) *	2011-06-16	2012-12-20	Solace Lifesciences, Inc.	Systems and methods for balancing and maintaining the health of the human autonomic nervous system
RU2496496C1 (ru) *	2012-10-04	2013-10-27	Исаак Григорьевич Гитлин	Фармацевтическая композиция, обладающая гамк-ергической активностью
CN108024997A (zh)	2015-07-17	2018-05-11	奥维德医疗公司	用加波沙朵治疗发育障碍的方法
KR20230050474A (ko) *	2016-08-11	2023-04-14	오비드 테라퓨틱스 인크.	간질 장애의 치료를 위한 방법 및 조성물
US20180338959A1 (en) *	2017-05-24	2018-11-29	Ovid Therapeutics Inc.	Treatment of depressive disorders
GB2571696B (en)	2017-10-09	2020-05-27	Compass Pathways Ltd	Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102049526B1 (ko) *	2018-06-05	2019-11-27	충남대학교산학협력단	Gaba를 유효성분으로 하는 항결핵 약학 조성물
KR102049522B1 (ko) *	2018-06-05	2019-11-27	충남대학교산학협력단	Gaba를 유효성분으로 하는 살모넬라 감염질환의 예방 및 치료용 조성물
EP3833351A4 (en)	2018-09-20	2021-10-13	Ovid Therapeutics Inc.	USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
KR20210110585A (ko)	2018-11-21	2021-09-08	썰테고 테라퓨틱스 아이엔씨.	자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
MX2021007224A (es)	2018-12-17	2021-09-23	Ovid Therapeutics Inc	Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
KR20220008824A (ko)	2019-04-17	2022-01-21	컴퍼스 패쓰파인더 리미티드	실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
US11364228B2 (en)	2019-12-18	2022-06-21	Ovid Therapeutics Inc.	Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
IL298334A (en)	2020-05-20	2023-01-01	Certego Therapeutics Inc	Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
CN114404437A (zh) *	2022-03-15	2022-04-29	山东中医药大学	没食子酰芍药苷在制备gabaa受体抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4362731A (en) *	1980-09-01	1982-12-07	Sandoz Ltd.	Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US5120723A (en) *	1987-08-25	1992-06-09	University Of Southern California	Method, compositions, and compounds for modulating brain excitability
CA2118938A1 (en) *	1991-09-13	1993-04-01	Kelvin W. Gee	Novel gabaa receptor with steroid binding sites
US5206415A (en) *	1991-12-20	1993-04-27	Washington University	Tricyclic steroid analogs
CZ300694A3 (en) *	1993-12-02	1996-05-15	Akzo Nobel Nv	Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
BR9509764A (pt) *	1994-11-23	1998-07-07	Cocensys Inc	Série androstano e pregnano para modulação alostérica de receptor de gaba
US5776959A (en) *	1995-06-05	1998-07-07	Washington University	Anticonvulsant and anxiolytic lactam and thiolactam derivatives
PT837874E (pt) *	1995-06-06	2005-03-31	Euro Celtique Sa	Esteroides neuroactivos da serie androstano e pregnano
IT1290003B1 (it) *	1997-03-03	1998-10-19	Angelini Ricerche Spa	Uso di pivagabina per preparare composizioni farmaceutiche
GB9801208D0 (en) *	1998-01-21	1998-03-18	Merck Sharp & Dohme	Therapeutic agents
DK1098871T3 (da) *	1998-07-22	2003-10-27	Akzo Nobel Nv	Phenylesterderivater af alfa-aminosyrer
BR0016201A (pt) *	1999-12-08	2002-08-13	Warner Lambert Co	Método para a sìntese estereosseletiva de aminoácidos cìclicos

2001
- 2001-11-16 AR ARP010105378A patent/AR031473A1/es unknown
- 2001-11-20 BR BR0115668-3A patent/BR0115668A/pt not_active Application Discontinuation
- 2001-11-20 AU AU2351402A patent/AU2351402A/xx active Pending
- 2001-11-20 EP EP01996378A patent/EP1337247B1/en not_active Expired - Lifetime
- 2001-11-20 NZ NZ525520A patent/NZ525520A/en unknown
- 2001-11-20 EA EA200300594A patent/EA007287B1/ru not_active IP Right Cessation
- 2001-11-20 YU YU39003A patent/YU39003A/sh unknown
- 2001-11-20 HR HR20030404A patent/HRP20030404A2/hr not_active Application Discontinuation
- 2001-11-20 CN CNB018190936A patent/CN1318027C/zh not_active Expired - Fee Related
- 2001-11-20 JP JP2002542383A patent/JP4152186B2/ja not_active Expired - Fee Related
- 2001-11-20 AU AU2002223514A patent/AU2002223514B2/en not_active Ceased
- 2001-11-20 UA UA2003054188A patent/UA77403C2/uk unknown
- 2001-11-20 DK DK01996378T patent/DK1337247T3/da active
- 2001-11-20 IL IL15558701A patent/IL155587A0/xx unknown
- 2001-11-20 PL PL36105101A patent/PL361051A1/xx unknown
- 2001-11-20 SK SK768-2003A patent/SK7682003A3/sk not_active Application Discontinuation
- 2001-11-20 ES ES01996378T patent/ES2266308T3/es not_active Expired - Lifetime
- 2001-11-20 DE DE60122368T patent/DE60122368T2/de not_active Expired - Lifetime
- 2001-11-20 MX MXPA03004349A patent/MXPA03004349A/es active IP Right Grant
- 2001-11-20 AT AT01996378T patent/ATE336242T1/de active
- 2001-11-20 KR KR1020037006754A patent/KR100865651B1/ko not_active Expired - Fee Related
- 2001-11-20 CA CA002429220A patent/CA2429220C/en not_active Expired - Fee Related
- 2001-11-20 ME MEP-64/08A patent/MEP6408A/xx unknown
- 2001-11-20 PT PT01996378T patent/PT1337247E/pt unknown
- 2001-11-20 HU HU0400505A patent/HUP0400505A3/hu unknown
- 2001-11-20 CZ CZ20031383A patent/CZ20031383A3/cs unknown
- 2001-11-20 WO PCT/DK2001/000773 patent/WO2002040009A1/en not_active Ceased
- 2001-11-20 SI SI200130619T patent/SI1337247T1/sl unknown
2003
- 2003-04-29 ZA ZA2003/03289A patent/ZA200303289B/en unknown
- 2003-04-30 IS IS6803A patent/IS2427B/is unknown
- 2003-05-01 US US10/430,704 patent/US20040024038A1/en not_active Abandoned
- 2003-05-20 NO NO20032271A patent/NO20032271D0/no not_active Application Discontinuation
- 2003-06-13 BG BG107909A patent/BG107909A/bg unknown
2006
- 2006-10-20 CY CY20061101505T patent/CY1106209T1/el unknown
2008
- 2008-06-27 US US12/163,883 patent/US20090143435A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AR031473A1 (es)	2003-09-24
US20090143435A1 (en)	2009-06-04
SK7682003A3 (en)	2003-10-07
US20040024038A1 (en)	2004-02-05
CA2429220C (en)	2009-09-15
NZ525520A (en)	2005-04-29
DK1337247T3 (da)	2006-12-04
HRP20030404A2 (en)	2005-04-30
IL155587A0 (en)	2003-11-23
IS2427B (is)	2008-10-15
CN1318027C (zh)	2007-05-30
DE60122368D1 (de)	2006-09-28
CZ20031383A3 (cs)	2003-08-13
KR20030065517A (ko)	2003-08-06
HK1075010A1 (en)	2005-12-02
JP2004513921A (ja)	2004-05-13
KR100865651B1 (ko)	2008-10-29
MXPA03004349A (es)	2003-08-19
PL361051A1 (en)	2004-09-20
MEP6408A (xx)	2010-02-10
SI1337247T1 (sl)	2006-12-31
PT1337247E (pt)	2006-11-30
AU2351402A (en)	2002-05-27
NO20032271L (no)	2003-05-20
EA200300594A1 (ru)	2003-10-30
UA77403C2 (en)	2006-12-15
BR0115668A (pt)	2003-09-02
EA007287B1 (ru)	2006-08-25
EP1337247B1 (en)	2006-08-16
ZA200303289B (en)	2005-07-27
IS6803A (is)	2003-04-30
ES2266308T3 (es)	2007-03-01
HUP0400505A2 (hu)	2004-07-28
EP1337247A1 (en)	2003-08-27
CA2429220A1 (en)	2002-05-23
CY1106209T1 (el)	2011-06-08
HUP0400505A3 (en)	2008-08-28
NO20032271D0 (no)	2003-05-20
YU39003A (sh)	2006-05-25
ATE336242T1 (de)	2006-09-15
AU2002223514B2 (en)	2006-11-30
WO2002040009A1 (en)	2002-05-23
JP4152186B2 (ja)	2008-09-17
DE60122368T2 (de)	2007-08-09
CN1592616A (zh)	2005-03-09

Publication	Publication Date	Title
AU2002223514B2 (en)	2006-11-30	Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
AU2002223514A1 (en)	2002-08-01	Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
KR100221854B1 (ko)	1999-09-15	드롤록시펜을 포함하는 전립선 질환을 치료하기 위한 약학 조성물
US8119619B2 (en)	2012-02-21	Pregnane steroids and their use in the treatment of CNS disorders
AU2013258566B2 (en)	2017-03-16	Pyrazole derivative and use thereof for medical purposes
JP2005527599A (ja)	2005-09-15	肥満および摂食障害におけるゾニサミドの使用
US20070142266A1 (en)	2007-06-21	Combination comprising a P-gp inhibitor and an anti-epileptic drug
JP2009533413A (ja)	2009-09-17	鎮痛剤およびビタミンを含む医薬組成物
MXPA01012794A (es)	2002-09-02	Composicion farmaceutica para la terapia de sintomas del tracto urinario inferior.
HK1075010B (en)	2008-01-25	Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
BR122025019564A2 (pt)	2025-10-28	Dispersão seca por pulverização, composição para sua formulação e método de fabricação da mesma, forma de dosagem sólida e seu método de fabricação, e uso de um inibidor de piridazinona trpc5 para tratar dor, ansiedade ou depressão
AU709606B2 (en)	1999-09-02	Use of droloxifene for the treatment of prostatic diseases endometriosis and obesity
EP4568689A1 (en)	2025-06-18	Compositions and use in methods for treating a cognitive deficit
HK40112370A (en)	2025-01-17	Methods of dosing of apical sodium-dependent bile acid transporter inhibitors (asbtis)